|| Checking for direct PDF access through Ovid
India is home to a large patient population of both rheumatoid arthritis (RA) and tuberculosis (TB). As the usage of biologic agents in RA increases in India, the issue of TB reactivation and prophylaxis becomes very pertinent. The consensus view of an expert group from the Indian Rheumatology Association is presented. Tuberculin testing has limited utility in India and isoniazid prophylaxis seems to be a reasonable option. It is hoped that this report shall pave the way for formal guidelines.